Newsroom press releases

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)

Products Molecular

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)

Products Molecular

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)

Products Molecular

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)

Products Molecular

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)

Products Immunodiagnostic

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)

Products Molecular

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)

Financial Disclosures

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)

Financial Disclosures

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)

Financial Disclosures

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)

Financial Disclosures

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)

Financial Disclosures

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)

Financial Disclosures

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)

Products Molecular

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)

Products Molecular